Name | N-[[(5S)-3-[3-fluoro-4-[4-[(2H-triazol-4-ylmethylamino)methyl]phenyl]phenyl]-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide |
---|---|
Synonyms |
RX-1741
N-{[(5S)-3-(2-Fluoro-4'-{[(1H-1,2,3-triazol-4-ylmethyl)amino]methyl}-4-biphenylyl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide Radezolid UNII-53PC6LO35W RX-103 Acetamide, N-[[(5S)-3-[2-fluoro-4'-[[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl][1,1'-biphenyl]-4-yl]-2-oxo-5-oxazolidinyl]methyl]- |
Description | Radezolid is a novel oxazolidinone antibiotic agent. |
---|---|
Related Catalog | |
In Vitro | Radezolid MICs are systematically equal to or lower (up to 3 log2 dilutions) than those of linezolid for all linezolid-susceptible strains, with an 8-fold difference for the linezolid-resistant strains. Radezolid shows a greater potency than linezolid, independent of the bacteria tested, when concentrations are expressed on a weight (mg/L) basis. Radezolid shows an improved potency compared to that of linezolid when concentrations are expressed on a weight (mg/L) basis[1]. Radezolid and TR-700 perform well against 3-copy G2447T, G2576T, and G2576T/T2571C mutants[2]. |
Cell Assay | Antibiotic accumulation is determined following the general procedure, and the cellular content of [14C]radezolid is assayed in cell lysates by liquid scintillation counting (lowest limit of detection, 0.003 mg/liter; linear response between 0.01 and 0.78 mg/liter; R2=0.999). All cell drug contents are expressed by reference to the total cell protein content and converted into apparent total cell concentrations using a conversion factor of 5 μL per mg of cell protein. |
References |
Density | 1.3±0.1 g/cm3 |
---|---|
Boiling Point | 712.5±60.0 °C at 760 mmHg |
Molecular Formula | C22H23FN6O3 |
Molecular Weight | 438.455 |
Flash Point | 384.7±32.9 °C |
Exact Mass | 438.181580 |
PSA | 112.24000 |
LogP | 2.28 |
Vapour Pressure | 0.0±2.3 mmHg at 25°C |
Index of Refraction | 1.612 |
~% 869884-78-6 |
Literature: US2010/234615 A1, ; Page/Page column 35 ; |